University of Colorado
Welcome,         Profile    Billing    Logout  
 562 Trials 
2095 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Thompson, John
NCT05307341: Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)

Recruiting
4
100
US
sufentanil, sufentanil (DSUVIA)
More Foundation
Pain
06/23
06/23
RECOVER-AUTO, NCT06305780: NOMIC Platform Protocol

Recruiting
2
380
US
IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care
Kanecia Obie Zimmerman
Long COVID, Long Covid19, Long Covid-19
12/25
03/26
MAGNIFY, NCT05893537: Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).

Active, not recruiting
2
100
US
Active Comparator CT1812, Placebo Comparator
Cognition Therapeutics
Age-Related Macular Degeneration
07/27
08/27
PYNNACLE, NCT04585750: The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation

Recruiting
1/2
230
Europe, US, RoW
PC14586, rezatapopt, pembrolizumab, KEYTRUDA®, MK-3475, KEYNOTE-D79, MK-3475-D79
PMV Pharmaceuticals, Inc, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer
03/26
07/26
NCT03377569: Subcortical Oscillations in Human Sleep Dysregulation

Active, not recruiting
N/A
15
US
Sleep, PD and DBS
University of Colorado, Denver
Parkinson Disease, REM Behavior Disorder
08/20
12/24
NCT04620551: Adaptive Neurostimulation to Restore Sleep in Parkinson's Disease

Active, not recruiting
N/A
20
US
Sub-clinical stimulation
University of Nebraska, Stanford University, University of Colorado, Denver, University of Pennsylvania
Parkinson Disease, Sleep Fragmentation
06/25
06/25
Gonzalez, Rene
NCT05089370: Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Active, not recruiting
1/2
8
US
Oral Decitabine/Cedazuridine (DEC-C) in Combination with Nivolumab
University of Colorado, Denver, National Comprehensive Cancer Network, Taiho Oncology, Inc.
Malignant Melanoma
07/25
07/26
Kinsella, John P
NCT03310346: Registry of Preterm Newborns With Severe Pulmonary Hypertension

Completed
N/A
232
US
University of Colorado, Denver, Mallinckrodt
Pulmonary Hypertension, Preterm Infant
07/22
07/22
Sherman, Scott E
NCT04063267: Electronic Cigarettes as a Harm Reduction Strategy in Individuals With Substance Use Disorder

Completed
2
48
US
E cigarettes, Nicotine Replacement Therapy
NYU Langone Health
Cigarette Smoking, Addiction, E Cig Use
06/24
06/24
SHIMMER, NCT05225415: Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects with Mild to Moderate Dementia with Lewy Bodies

Completed
2
130
US
CT1812
Cognition Therapeutics, National Institute on Aging (NIA)
Dementia with Lewy Bodies
11/24
11/24
NCT06021756: Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease

Active, not recruiting
1
9
US
Intervention: Ketamine, Intervention: Ketamine i.v.
University of Arizona, Scott Richards
Levodopa-Induced Dyskinesia, Parkinson's Disease
08/22
08/23
Allo-PD, NCT06263010: Allopregnanolone As a Regenerative Treatment for Parkinson's Disease

Active, not recruiting
1
10
US
Allopregnanolone
Roberta Brinton
Parkinson Disease
05/25
05/25
NCT04465318: Electronic Cigarettes as a Harm Reduction Strategy Among Patients With COPD

Completed
N/A
146
US
E-cigarette (EC), Nicotine Replacement Therapy (NRT), Smoking Harm Reduction Counseling Sessions
NYU Langone Health
COPD
03/23
03/23
FIESTA II, NCT03979885: Financial Incentives for Smoking Treatment II

Enrolling by invitation
N/A
1058
US
Smoking cessation counseling (Quitline), Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy), Financial incentives for smoking cessation, Financial incentives for use of evidence-based smoking cessation therapies
University of California, Los Angeles, NYU Langone Health, Olive View-UCLA Education & Research Institute
Smoking Cessation, Tobacco Use Cessation
12/24
06/25
NCT03477435: Comparing an Opt-out to an opt-in Approach for Smoking Cessation in VA Primary Care Clinics

Active, not recruiting
N/A
1365
US
Staff training and academic detailing
VA Office of Research and Development
Tobacco Use
04/25
04/25
NCT05130788: WeChat Quit Coach Pilot Study

Active, not recruiting
N/A
150
US
WeChat Quit Coach, Leaflet, Optional Nicotine Replacement Therapy (NRT) Patches or Lozenges, Habitrol, Nicorette
NYU Langone Health, Asian Americans for Equality, Chinese American Planning Council, National Institute on Minority Health and Health Disparities (NIMHD)
Smoking Cessation
12/24
12/24
NCT04403295: Collaborative Specialty Care for Gulf War Illness

Recruiting
N/A
220
US
Collaborative Specialty Care, e-consultation
VA Office of Research and Development
Gulf War Illness
03/25
05/25
Perlman, Susan
NEAT, NCT06193200: Evaluate the Neurological Effects of EryDex on Subjects With A-T

Recruiting
3
106
Europe, US
Dexamethasone sodium phosphate, DSP, Placebo
Quince Therapeutics S.p.A., Biotrial
Ataxia Telangiectasia
08/25
09/25
OLE_NEAT, NCT06664853: Open-Label Extension of EryDex Study IEDAT-04-2022

Recruiting
3
106
Europe, US
Dexamethasone sodium phosphate
Quince Therapeutics S.p.A., Biotrial
Ataxia Telangiectasia
11/26
11/26
STRIDES, NCT05490563: - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Terminated
2/3
23
Europe, US, RoW
SLS-005, Placebo
Seelos Therapeutics, Inc.
Spinocerebellar Ataxia Type 3
11/23
11/23
NCT03759678 / 2018-004407-39: N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

Recruiting
2
39
Europe, US
IB1001, N-Acetyl-L-Leucine
IntraBio Inc
Ataxia Telangiectasia, Louis Bar Syndrome
12/24
03/25
NCT05526391 / 2022-000336-28: A Study of TAK-341 in Treatment of Multiple System Atrophy

Active, not recruiting
2
159
Europe, Japan, US
TAK-341, MEDI1341, Placebo
Takeda, AstraZeneca
Multiple System Atrophy
07/25
07/25
NCT05923866: A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

Recruiting
2
80
US
ONO-2808, Placebo
Ono Pharmaceutical Co. Ltd
Multiple System Atrophy (MSA)
08/25
08/25
NCT03487367: Clinical Trial Readiness for SCA1 and SCA3

Active, not recruiting
N/A
200
US
The Methodist Hospital Research Institute, University of Michigan, University of Minnesota, University of Utah, University of California, Los Angeles, University of Chicago, University of South Florida, Harvard University, Johns Hopkins University, University of Florida, Columbia University, Emory University, University of California, San Francisco, University of Alabama at Birmingham, University of Colorado, Denver, University of Rochester, Stanford University, Northwestern University, German Center for Neurodegenerative Diseases (DZNE), Institut de Recherche sur la Moelle épinière et l'Encéphale, University of Pennsylvania, Ohio State University, University of Iowa
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia 3
12/23
12/23
NCT06445712: Examining the Role of Pain in the Link Between Early Childhood Adversity and Psychopathology

Recruiting
N/A
40
US
Parental Support Cold Pressor Task
Washington University School of Medicine, National Center for Advancing Translational Sciences (NCATS)
Child Development
04/25
04/25
NCT01060371: Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias

Recruiting
N/A
800
US
All Participants
University of Florida, National Ataxia Foundation, University of California, Los Angeles
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6
05/24
05/24
IDEA, NCT04268147: Instrumented Data Exchange for Ataxia Study

Completed
N/A
128
US
University of Chicago, Pfizer, Biogen, APDM Wearable Technologies
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
04/24
06/24
NCT06623890: A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it for the First Time

Recruiting
N/A
300
Europe, US, RoW
Omaveloxolone, SKYCLARYS, BIIB141
Reata, a wholly owned subsidiary of Biogen
Friedreich Ataxia
10/29
10/29
FA-COMS, NCT03090789: FA Clinical Outcome Measures

Active, not recruiting
N/A
2000
Canada, US, RoW
Friedreich's Ataxia Research Alliance, University of Rochester, Children's Hospital of Philadelphia
Friedreich Ataxia, Neuro-Degenerative Disease
01/30
01/30
UNIFAI, NCT06016946: Friedreich Ataxia Global Clinical Consortium UNIFIED Natural History Study

Recruiting
N/A
3000
Europe, Canada, US, RoW
Friedreich's Ataxia Research Alliance
Friedreich Ataxia
01/48
01/48
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort

Recruiting
N/A
35000
Europe, Canada, US, RoW
CHDI Foundation, Inc.
Huntington's Disease
01/62
01/62
Messersmith, Wells
NCT03781154: Predictors of Physical Activity Maintenance in Colorectal Cancer Survivors

Completed
3
31
US
Group Exercise
University of Colorado, Denver, American Cancer Society, Inc., Colorado State University
Colorectal Cancer
06/23
06/23
AGICC, NCT02723331: Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates

Active, not recruiting
2
48
US
Nab paclitaxel, Abraxane, Gemcitabine, Gemzar
Academic Thoracic Oncology Medical Investigators Consortium, Celgene Corporation, Criterium, Inc., University of Colorado, Denver
Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
12/22
05/25
C-800-25, NCT05608044: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

Active, not recruiting
2
234
Europe, US, RoW
Botensilimab, AGEN1181, Balstilimab, AGEN2034, Standard of Care
Agenus Inc.
Metastatic Colorectal Cancer
02/25
07/25
NCT05167409: A Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer

Active, not recruiting
2
48
US
Evorpacept (ALX148), evorpacept, Cetuximab, Erbitux, Pembrolizumab, Keytruda
University of Colorado, Denver, ALX Oncology Inc., Merck Sharp & Dohme LLC, Eli Lilly and Company, Criterium, Inc., Academic GI Cancer Consortium (AGICC)
Microsatellite Stable Metastatic Colorectal Cancer
12/25
03/26
NCT02521844: A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours

Active, not recruiting
1
89
US, RoW
ETC-1922159, Pembrolizumab
EDDC (Experimental Drug Development Centre), A*STAR Research Entities, PPD DEVELOPMENT, LP
Solid Tumors
10/24
10/24
NX-1607-101, NCT05107674: A Study of NX-1607 in Adults With Advanced Malignancies

Recruiting
1
345
Europe, US
NX-1607, Cbl-b Inhibitor, Paclitaxel
Nurix Therapeutics, Inc.
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
08/26
02/28
NCT02955446: Compassionate Use Protocol for PF-03084014 in Patients With Advanced Solid Tumor Malignancies

No Longer Available
N/A
US
PF-03084014, Gamma Secretase Inhibitor
University of Colorado, Denver, SpringWorks Therapeutics, Inc.
Neoplasm, Desmoid Tumor
 
 
Kutner, Jean S
NCT04466865: A Communication Tool to Assist Older Adults Facing Dialysis Choices

Active, not recruiting
N/A
407
US
Best Case/Worst Case communication tool training
University of Wisconsin, Madison, National Institute on Aging (NIA), University of Pittsburgh, University of Vermont, Johns Hopkins University, University of Colorado, Denver, Icahn School of Medicine at Mount Sinai, University of Washington, West Virginia University, Columbia University, Medical College of Wisconsin, The Palliative Care Research Cooperative Group, Northwestern University
Palliative Care, Kidney Failure, Chronic, Decision Making, Decision Support Techniques, Renal Dialysis, Dialysis, Kidney Diseases, Nephrologists, Decision Aid, End of Life, End-Stage Renal Disease, Late-Stage Renal Disease, Communication, Life-Supporting Treatments
10/25
10/25
Campbell, Thomas B
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial

Active, not recruiting
4
446
Europe, Canada, US, RoW
Faricimab
McMaster University, Hoffmann-La Roche
Diabetic Macular Edema
12/26
12/26
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide

Active, not recruiting
4
222
US
Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
11/24
11/24
STOMP, NCT05534984: Study of Tecovirimat for Human Mpox Virus

Active, not recruiting
3
719
Japan, US, RoW
Tecovirimat Oral Capsule, Placebo, Tecovirimat Oral Capsule (Open Label)
National Institute of Allergy and Infectious Diseases (NIAID), SIGA Technologies
MPOX
10/24
09/25
PURGE-C, NCT04042740: Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed
2
45
US, RoW
Glecaprevir/Pibrentasvir (G/P), Mavyret
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, AbbVie, National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C Infection, HIV Infection
05/23
08/23
NCT05414851: Low-Carbohydrate and Plant-Based Dietary Effects on Vascular Health

Completed
N/A
45
US
Whole-Food, Plant-Based Diet and Low-Carbohydrate Diet
University of Rochester
Heart Disease, Ischemic, Hyperlipidemias, Hypertension
04/24
04/24
Roth, Michael D
NCT04614662: Symptom Screening Linked to Care Pathways

Completed
3
445
Canada, US
SPARK Symptom Screening Linked to Feedback to Providers
The Hospital for Sick Children, National Cancer Institute (NCI)
Pediatric Cancer, Quality of Life
10/23
10/23
NCT03221257: Scleroderma Lung Study III - Combining Pirfenidone With Mycophenolate

Completed
2
51
US
Pirfenidone (PFD), Esbriet, Placebo (Plac), Inactive capsule, Mycophenolate Mofetil (MMF), generic for Cellcept
Michael Roth, University of Michigan, Genentech, Inc., University of California, Los Angeles
Scleroderma, Systemic, Interstitial Lung Disease
03/22
06/22
NCI-2021-10994, NCT05169151: Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study

Withdrawn
N/A
500
US
Smartphone Application, App, Smartphone App
M.D. Anderson Cancer Center, National Cancer Institute (NCI)
Central Nervous System Neoplasm, Hodgkin Lymphoma, Malignant Solid Neoplasm, Non-Hodgkin Lymphoma, Sarcoma
04/23
04/23
MOST EMPOWER, NCT04317417: Optimizing An Emotion Regulation Intervention

Active, not recruiting
N/A
352
US
EMPOWER
Wake Forest University Health Sciences, National Cancer Institute (NCI)
Cancer
03/25
03/25
Bull, Sheana
NCT03973931: Personalized Patient Data and Behavioral Nudges to Improve Adherence to Chronic Cardiovascular Medications

Active, not recruiting
N/A
9501
US
Nudge
University of Colorado, Denver, National Heart, Lung, and Blood Institute (NHLBI)
Cardiovascular Diseases, Adherence, Medication, Medication Adherence, Diabetes Mellitus, Hypertension, Hyperlipidemias, Coronary Artery Disease, Atrial Fibrillation
01/24
06/24
Anderson, Peter
NCT05140954: The Women TAF-FTC Benchmark Study

Completed
2/3
54
RoW
co-formulated 25mg TAF/ 200mg FTC, Descovy
University of Washington, Kenya Medical Research Institute, University of Colorado, Denver, Gilead Sciences
HIV Infections
12/23
12/23
NCT06435026: Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1

Recruiting
2
54
RoW
FTC/TDF 200mg/300mg, PrEP, FTC/TDF 300mg/450mg, FTC/TDF 400mg/600mg
University of North Carolina, Chapel Hill, National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Prevention, Pregnancy
02/25
02/25
NCT05057858: The Women TDF-FTC Benchmark Study

Active, not recruiting
2
72
RoW
co-formulated 300 mg TDF/ 200mg FTC, Truvada
University of Washington, University of Colorado, Denver, Kenya Medical Research Institute, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
01/25
01/25
Tracer Pilot, NCT04535934: Novel Approaches for Quantitative Assessment of Adherence

Completed
N/A
15
US
Adenine 5+ (five stable-labeled nitrogens), taggant
University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
Healthy
11/22
11/22
ACT, NCT05335590: Adherence and Clinical Correlates in Persons With HIV on TAF

Active, not recruiting
N/A
384
US
University of Colorado, Denver
Hiv
05/25
05/25
NCT04065347: Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)

Completed
N/A
84
US
Digital Pill, etectRx ID-Cap System
University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
HIV/AIDS, Adherence, Medication
05/23
05/23
HOME-1, NCT04979728: HIV Outpatient Monitoring Evaluation Through Self-collection of Dried Blood Spots

Recruiting
N/A
150
US
At Home Self-Collections, Tasso-M20, Tasso+, Mitra, DBS by fingerstick
University of Colorado, Denver, National Institute of Allergy and Infectious Diseases (NIAID)
HIV Treatment, HIV Prevention
12/25
12/25
Shaheen, Nicholas
NCT06732388: Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

Not yet recruiting
2
64
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Endoscopic Procedure, Endoscopic Examination, Endoscopy, ES, Itraconazole, Lozanoc, Oriconazole, R 51,211, Sporanox, Placebo Administration, Questionnaire Administration, Radiofrequency Ablation, Ablation, Radiofrequency, Radiofrequency Interstitial Ablation, RFA
National Cancer Institute (NCI)
Barrett Esophagus, Clinical Stage I Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma
01/28
01/28
NCT04939051: Obeticholic Acid for Prevention in Barrett's Esophagus

Recruiting
2
30
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Esophageal Biopsy, Biopsy of Esophagus, Esophagogastroduodenoscopy, EGD, Upper Endoscopy, Liver Ultrasonographic Elastography, Fibroscan, TE, Transient Elastography, VCTE, Vibration-Controlled Transient Elastrography, Obeticholic Acid, INT-747, Ocaliva, Placebo Administration, Questionnaire Administration
National Cancer Institute (NCI)
Barrett Esophagus, Esophageal Adenocarcinoma
09/25
09/26
NCT03243734: trūFreeze® Palliative Esophageal Cancer

Completed
N/A
49
US
trūFreeze® System spray cryotherapy
US Endoscopy Group Inc.
Esophageal Cancer
07/22
03/24
NCT04316975: Utility Of Mutational Load As A Predictor For Endoscopic Treatment Response In Barrett's Esophagus

Completed
N/A
75
US
Study Driven Procurement of Biopsies, Research Biopsies
University of North Carolina, Chapel Hill, Interpace Diagnostics Corporation
Barretts Esophagus With Dysplasia, Intramucosal Adenocarcinoma
12/23
12/23
NCT06687603: Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms

Not yet recruiting
N/A
800
US
EsoCheck, EsoGuard
Case Comprehensive Cancer Center
Barrett Esophagus, Gastroesophageal Reflux, Esophageal Adenocarcinoma
09/28
09/29
BEECAB, NCT02427269: University of North Carolina (UNC) Barrett's Esophagus and Esophageal Cancer Biorepository

Enrolling by invitation
N/A
1000
US
Specimen Collection
University of North Carolina, Chapel Hill
Barrett's Esophagus, Esophageal Cancer, Intramucosal Adenocarcinoma
05/25
05/25
ReBET, NCT03554356: Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)

Recruiting
N/A
70
US
CryoBalloon Focal Ablation System
University of North Carolina, Chapel Hill, PENTAX of America, Inc., Johns Hopkins University
Barrett Esophagus, Intestinal Metaplasia, Esophageal Dysplasia
12/26
12/26
SWAT-BE, NCT05530343: Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance

Recruiting
N/A
2298
US
Seattle protocol, WATS3D brushings
University of Colorado, Denver
Barrett Esophagus, Barretts Esophagus With Dysplasia, Esophageal Adenocarcinoma
03/26
03/26
SURVENT, NCT05753748: Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia

Recruiting
N/A
680
US
Endoscopic Eradication Therapy
University of Colorado, Denver, Baylor University, University of North Carolina, Medical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Barretts Esophagus With Dysplasia, Barrett Esophagus, Esophageal Adenocarcinoma
02/28
02/28
FBE, NCT00288119: Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

Recruiting
N/A
2000
US
Balloon Capsule Device, Esophageal Sampling Device BESD-001, Endoscopy, EGD
Case Western Reserve University, University Hospitals Cleveland Medical Center, Washington University School of Medicine, Fred Hutchinson Cancer Center, University of Washington, Mercy Medical Center, Johns Hopkins University, Mayo Clinic, University of North Carolina, Chapel Hill, The Cleveland Clinic, University of Pennsylvania, Columbia University, VA Puget Sound Health Care System
Barrett's Esophagus, Esophageal Neoplasm
07/28
07/28
Agulnik, Mark
MOTION, NCT05059262 / 2020-004883-25: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
120
Europe, Canada, US, RoW
vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
ARGSARC, NCT05712694: Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects with Leiomyosarcoma

Recruiting
3
300
Canada, US, RoW
ADI PEG20, Pegargiminase, Placebo
Polaris Group
Soft Tissue Sarcoma
12/27
12/27
SUNRISELMS, NCT05269355 / 2022-000073-12: A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

Active, not recruiting
2/3
360
Europe, Canada, US, RoW
Unesbulin, PTC596, Dacarbazine, DTIC, Placebo
PTC Therapeutics, PTC Therapeutics, Inc.
Leiomyosarcoma
06/24
06/24
RINGSIDE, NCT04871282 / 2020-005833-34: A Study of AL102 in Patients With Progressing Desmoid Tumors

Active, not recruiting
2/3
192
Europe, US, RoW
AL102, Placebo
Immunome, Inc.
Desmoid, Desmoid Tumor
10/25
10/26
NCT05432791: Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working

Active, not recruiting
2/3
190
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Pazopanib, GW786034, Temozolomide, CCRG-81045, Gliotem, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temizole, Temodal, Temodar, Temomedac, TMZ, Trabectedin, Ecteinascidin, Ecteinascidin 743, ET 743, ET-743, ET743, Yondelis, Transthoracic Echocardiography, TTE
National Cancer Institute (NCI)
Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
03/30
03/30
SPEARHEAD-1, NCT04044768 / 2019-000589-39: Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

Oct 2022 - Jun 2023: BLA submission for treatment of synovial sarcoma
Checkmark Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Nov 2022 - Nov 2022: Data from cohort 1 of SPEARHEAD-1 trial for synovial sarcoma or myxoid round cell liposarcoma
Checkmark Pooled analysis data from trials for sarcoma at AACR 2022
Jun 2022 - Jun 2022: Pooled analysis data from trials for sarcoma at AACR 2022
More
Active, not recruiting
2
52
Europe, Canada, US
afamitresgene autoleucel (previously ADP-A2M4)
Adaptimmune, Adaptimmune LLC
Synovial Sarcoma, Myxoid Liposarcoma
08/21
04/38
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
NCT04200443: Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma

Active, not recruiting
2
72
US
Cabozantinib, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZ
City of Hope Medical Center, National Cancer Institute (NCI)
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8, Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Leiomyosarcoma, Unresectable Soft Tissue Sarcoma
04/25
04/25
NCT04595747: Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)

Active, not recruiting
2
48
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Rogaratinib, BAY-1163877, BAY1163877
National Cancer Institute (NCI)
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma, Stage III Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8, Stage IV Gastric and Omental Gastrointestinal Stromal Tumor AJCC v8, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8
01/25
01/25
NCT04040205: Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration

Recruiting
2
44
US
Abemaciclib, Verzenio
Medical College of Wisconsin
Chondrosarcoma, Osteosarcoma, Soft Tissue Sarcoma
06/25
06/26
PRECISION 1, NCT05103358: Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes

Active, not recruiting
2
120
US, RoW
nab-sirolimus, ABI-009
Aadi Bioscience, Inc.
Tumor, Tumor, Solid, Metastasis, Metastatic Cancer, Cancer, Cancer Metastatic, Tumors, Neoplasms, Neoplasm Metastasis, Solid Tumor, Advanced Solid Tumor, Advanced Cancer, Malignant Solid Tumor, Malignant Solid Neoplasm, Malignant Neoplasm, Malignant Tumor, TSC, TSC1, TSC2, Metastatic Solid Tumor, Metastatic Neoplasm
12/24
12/25
NCT05580588: Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Terminated
2
14
US
SPH4336
Shanghai Pharma Biotherapeutics USA Inc.
Liposarcoma, Dedifferentiated
10/24
10/24
NCT05694871: Testing the Addition of Cemiplimab to Palbociclib for the Treatment of Advanced Dedifferentiated Liposarcoma

Active, not recruiting
2
77
US
Palbociclib, PD-0332991, Cemiplimab, Cemiplimab RWLC, Immunoglobulin G4, Magnetic Resonance Imaging, MRI, Computed Tomography, CAT Scan, CT Scan, Biospecimen collection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Advanced Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities AJCC V8, Unresectable Dedifferentiated Liposarcoma
05/27
05/27
APOLLO 613, NCT04593758: To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue

Completed
1/2
16
US
CPI-613 + Hydroxychloroquine
Cornerstone Pharmaceuticals
Sarcoma, Clear Cell
03/23
03/23
NCT05100628: A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma

Terminated
1
9
US
NOX66, Doxorubicin
Noxopharm Limited
Metastatic Soft-tissue Sarcoma
05/23
05/23
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
CFT8634-1101, NCT05355753: A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

Terminated
1
49
US
CFT8634
C4 Therapeutics, Inc.
Synovial Sarcoma, Soft Tissue Sarcoma
12/23
12/23
FHD-609-C-001, NCT04965753 / 2021-001488-25: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Terminated
1
55
Europe, US
FHD-609
Foghorn Therapeutics Inc., Foghorn Therapeutics Inc.
Advanced Synovial Sarcoma
12/23
12/23
NCT03391778 / 2018-004888-31: Adoptive Cell Therapy Long-term Follow-up (LTFU) Study

Recruiting
1
250
Europe, Canada, US, RoW
ADP adoptive cell therapy
Adaptimmune
Neoplasms
04/32
04/32
Flaig, Thomas W
NCT01309672: S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Checkmark ASCO-GU 2015
Feb 2015 - Feb 2015: ASCO-GU 2015
Completed
2
41
US
abiraterone acetate, Prednisone
SWOG Cancer Research Network, National Cancer Institute (NCI)
Prostate Cancer
11/16
04/24
NCI-2017-02296, NCT03375307: Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes

Recruiting
2
150
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Olaparib, AZD 2281, AZD-2281, AZD2281, KU 0059436, KU-0059436, KU0059436, Lynparza, Olanib, Olaparix, PARP Inhibitor AZD2281, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT
National Cancer Institute (NCI)
Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma, Metastatic Genitourinary System Carcinoma, Stage III Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8
12/25
12/25
NCT04963153: Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy

Recruiting
1
30
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Enfortumab Vedotin, AGS 22ME, AGS-22M6E, Anti-Nectin 4 ADC ASG-22CE, Anti-nectin-4 Monoclonal Antibody-Drug Conjugate AGS-22M6E, ASG 22CE, ASG-22CE, ASG22CE, Enfortumab Vedotin-ejfv, Padcev, Erdafitinib, Balversa, JNJ 42756493, JNJ-42756493, JNJ42756493, Multigated Acquisition Scan, Blood Pool Scan, Equilibrium Radionuclide Angiography, Gated Blood Pool Imaging, Gated Heart Pool Scan, MUGA, MUGA Scan, Multi-Gated Acquisition Scan, Radionuclide Ventriculogram Scan, Radionuclide Ventriculography, RNV Scan, RNVG, SYMA Scanning, Synchronized Multigated Acquisition Scanning
National Cancer Institute (NCI)
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Recurrent Urothelial Carcinoma, Stage IIIB Bladder Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8
09/25
09/25
PROBE, NCT04986865: A Study ATG-101 in Patients With Metastatic/Advanced Solid Tumors and Mature B-cell Non-Hodgkin Lymphomas

Recruiting
1
40
US, RoW
ATG-101
Antengene Biologics Limited
Advanced Solid Tumor, Metastatic Solid Tumor, Mature B-cell Non-Hodgkin Lymphoma
10/25
01/26
NCT05515978: Pragmatic Trial of Metformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patients

Recruiting
1
200
US
Metformin, Glucophage, Riomet, Glumetza, Lifestyle Modification
University of Colorado, Denver
Prostate Cancer
10/35
11/36
Goodman, Karyn A
ERASur, NCT05673148: Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, the Study

Recruiting
3
364
US
Stereotactic Ablative Radiotherapy, SABER, SABR/SBRT, Resection, Surgical resection, Microwave Ablation, Ablation, Chemotherapy, Chemo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, CT Scan, Magnetic Resonance Imaging, MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC V8
07/28
08/32
CALGB-80803, NCT01333033: PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy

Completed
2
257
US
Oxaliplatin, Leucovorin Calcium, Fluorouracil, Carboplatin, Paclitaxel, Positron Emission Tomography, Computed Tomography, Radiation Therapy
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer
11/15
04/23
GRECO-2, NCT04698915: Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer

Terminated
2
177
Europe, Canada, US
Drug GC4711, Placebo
Galera Therapeutics, Inc.
SBRT, Borderline Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer
11/23
11/23
NCT04166318: Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study

Recruiting
2
252
US
Capecitabine, Ro 09-1978/000, Xeloda, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-FU, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Intensity-Modulated Radiation Therapy, IMRT, Intensity Modulated RT, Intensity-Modulated Radiotherapy, Mitomycin, Ametycine, MITO, MITO-C, Mito-Medac, Mitocin, Mitocin-C, Mitolem, Mitomycin C, Mitomycin-C, Mitomycin-X, Mitomycine C, Mitosol, Mitozytrex, Mutamycin, Mutamycine, NCI-C04706, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI)
Anal Basaloid Carcinoma, Anal Canal Cloacogenic Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Margin Squamous Cell Carcinoma, Stage I Anal Cancer AJCC v8, Stage IIA Anal Cancer AJCC v8
12/29
12/29
ETCTN 10366, NCT04172532: Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Recruiting
1/2
98
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Hypofractionated Radiation Therapy, Hypofractionated, Hypofractionated Radiotherapy, hypofractionation, Radiation, Hypofractionated, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Peposertib, 3-Pyridazinemethanol, alpha-(2-Chloro-4-fluoro-5-(7-(4-morpholinyl)-4-quinazolinyl)phenyl)-6-methoxy-, (alphaS)-, M 3814, M-3814, M3814, MSC 2490484A, MSC-2490484A, MSC2490484A, Nedisertib, Placebo Administration
National Cancer Institute (NCI)
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
08/26
08/26
Rasouli, Neda
SIB, NCT04979130: Comparing Semaglutide Versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus

Recruiting
4
42
US
Semaglutide, Ozempic, PDS290 pen-injector, Placebo
University of Colorado, Denver, Novo Nordisk A/S
Type 2 Diabetes, Chronic Inflammation, Intestinal Permeability
12/23
12/23
TRANSCEND-T2D-2, NCT06260722: Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor

Recruiting
3
1250
Canada, US, RoW
Retatrutide, LY3437943, Semaglutide
Eli Lilly and Company
Diabetes Mellitus, Type 2
12/26
03/27
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

Recruiting
3
12500
Europe, Canada, Japan, US, RoW
Lepodisiran Sodium, LY3819469, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)
03/29
03/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
QWINT-1, NCT05662332: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

Completed
3
795
US, RoW
Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, T2D
07/24
07/24
 

Download Options